Inventor · disambiguated record
Adam Siddiqui-Jain
Also filed as: SIDDIQUI-JAIN ADAM
32 granted patents·23 pending applications·249 citations·filing 2003–2024
97Inventor score
Files withSUMITOMO PHARMA ONCOLOGY INC14TOLERO PHARMACEUTICALS INC11CYLENE PHARMACEUTICALS INC9SUMITOMO DAINIPPON PHARMA ONCOLOGY INC9FROST BIOLOGIC INC4
Top patents by PatentIndex Score
55 records- 0197US9758539B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Sep 12, 2017·24 cites·13 claims
- 0296US10835537B2Combination therapies for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Granted Nov 17, 2020·7 cites·6 claims
- 0396US10568887B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 25, 2020·10 cites·1 claims
- 0496US10259835B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2017·Granted Apr 16, 2019·17 cites·13 claims
- 0595US11530231B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Granted Dec 20, 2022·5 cites·21 claims
- 0695US10267787B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Apr 23, 2019·13 cites·13 claims
- 0794US10562925B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2020·10 cites·20 claims
- 0894US7326702B2Substituted quinobenzoxazine analogsCYLENE PHARMACEUTICALS INC·Filed 2006·Granted Feb 5, 2008·13 cites·37 claims
- 0993US11034710B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 15, 2021·7 cites·28 claims
- 1093US10132797B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2017·Granted Nov 20, 2018·15 cites·15 claims
- 1193US7612063B2Substituted quinobenzoxazine analogsCYLENE PHARMACEUTICALS INC·Filed 2008·Granted Nov 3, 2009·11 cites·28 claims
- 1292US10422788B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Sep 24, 2019·11 cites·19 claims
- 1392US7381720B2Substituted quinobenzoxazine analogsCYLENE PHARMACEUTICALS INC·Filed 2006·Granted Jun 3, 2008·15 cites·34 claims
- 1491US11279694B2Alvocidib prodrugs and their use as protein kinase inhibitorsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2017·Granted Mar 22, 2022·6 cites·4 claims
- 1591US10772872B2Antimitotic amides for the treatment of cancer and proliferative disordersFROST BIOLOGIC INC·Filed 2018·Granted Sep 15, 2020·3 cites·19 claims
- 1691US10682356B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Jun 16, 2020·7 cites·1 claims
- 1791US7141565B1Substituted quinobenzoxazine analogsCYLENE PHARMACEUTICALS INC·Filed 2004·Granted Nov 28, 2006·34 cites·54 claims
- 1890US11497756B2Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidibSUMITOMO PHARMA ONCOLOGY INC·Filed 2018·Granted Nov 15, 2022·4 cites·18 claims
- 1989US10016398B2Antimitotic amides for the treatment of cancer and proliferative disordersFROST BIOLOGIC INC·Filed 2015·Granted Jul 10, 2018·7 cites·21 claims
- 2087US7507727B2Substituted quinobenzoxazine analogs and methods of using thereofCYLENE PHARMACEUTICALS INC·Filed 2005·Granted Mar 24, 2009·11 cites·9 claims
- 2186US11129813B2Antimitotic amides for the treatment of cancer and proliferative disordersFROST BIOLOGIC INC·Filed 2020·Granted Sep 28, 2021·1 cites·20 claims
- 2285US7354916B2Substituted quinobenzoxazine analogsCYLENE PHARMACEUTICALS·Filed 2004·Granted Apr 8, 2008·16 cites·35 claims
- 2380US11013741B1AXL kinase inhibitors and use of the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted May 25, 2021·1 cites·11 claims
- 2479US2025197432A1CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of CancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 2577US12383533B2Antimitotic amides for the treatment of cancer and proliferative disordersFROST BIOLOGIC INC·Filed 2021·Granted Aug 12, 2025·0 cites·20 claims
- 2677US12338261B2Alvocidib prodrugs having increased bioavailabilitySUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Granted Jun 24, 2025·0 cites·10 claims
- 2776US12077554B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 2876US11040038B2Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 22, 2021·1 cites·11 claims
- 2973US2020131210A1Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3072US2020200737A1Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3168US2023165857A1Axl kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 3268US2023233557A1Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 3368US2021228582A1Combination therapies for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 3463US11471456B2Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Oct 18, 2022·0 cites·23 claims
- 3562US11400091B2AXL kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 2, 2022·0 cites·36 claims
- 3662US2012122804A1Substituted quinobenzoxazine analogsWHITTEN JEFFREY P·Filed 2007·Application pending·0 cites
- 3761US2024360135A1Imidazo[1,2-b]pyridazinyl compounds and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 3858US2008032286A1Competition Assay for Identifying Modulators of Quadruplex Nucleic AcidsCYLENE PHARACEUTICALS INC·Filed 2004·Application pending·0 cites
- 3958US2024197729A1ALK-5 Inhibitors and Uses ThereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 4056US11746103B2ALK-5 inhibitors and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Granted Sep 5, 2023·0 cites·27 claims
- 4155US2006183106A1Processes for identifying quadruplex-targeted antiviral moleculesSIDDIQUI-JAIN ADAM·Filed 2003·Application pending·0 cites
- 4254US2009181377A1HUMAN RIBOSOMAL DNA (rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOFCYLENE PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4353US2023090742A1Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 4452US11529350B2Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereofSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Dec 20, 2022·0 cites·51 claims
- 4551US2004005601A1Methods for targeting quadruplex DNAFiled 2003·Application pending·0 cites
- 4651US2022162200A1Pkm2 modulators and methods for their useSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 4750US2021277037A1Deuterated alvocidib and alvocidib prodrugsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Application pending·0 cites
- 4850US2007117770A1Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereofCYLENE PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 4950US2006286575A1MCL-1 quadruplex nucleic acids and uses thereofCYLENE PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 5049US2020237766A1Pkm2 activators in combination with reactive oxygen species for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Adam Siddiqui-Jain files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →